Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs H2O America — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while H2O America trades at $61.47 (market cap $2.57B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.5× H2O America's market cap, and H2O America pays a 2.86% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HTO | |
|---|---|---|
Market Cap | $39.89B | $2.57B |
Sector | Health | Technology |
52-Week High | $491.22 | $62.42 |
52-Week Low | $278.09 | $44.44 |
Enterprise Value | $38.15B | $4.29B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HTO trades at $61.47, showing minimal daily movement (+0.02%) with strong technical bullish signals from moving averages. The company maintains solid fundamentals with 12.87% net income margin and recent Q1 2026 earnings beat. Analyst consensus is strongly bullish with 80% buy ratings and a $61.33 price target, while the company continues its dividend program with a $0.44 H1-26 payment.
HTO presents a stable investment case with consistent profitability and dividend payments, though growth appears moderate. Key risks include execution of the $2.7 billion capex plan and competitive pressures in the utilities sector. The stock's current valuation appears reasonable with P/E of 21.05, suggesting potential for steady returns rather than explosive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
